Company Description
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.
The company’s products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD.
It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor.
In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform.
The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester.
IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | May 23, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Yujiro Hata |
Contact Details
Address: 5000 Shoreline Court, Suite 300 South San Francisco, California 94080 United States | |
| Phone | 650 443 6209 |
| Website | ideayabio.com |
Stock Details
| Ticker Symbol | IDYA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001676725 |
| CUSIP Number | 45166A102 |
| ISIN Number | US45166A1025 |
| Employer ID | 47-4268251 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yujiro S. Hata | President, Chief Executive Officer and Director |
| Andres Ruiz Briseno CPA | Principal Accounting Officer, Senior Vice President and Head of Finance and Investor Relations |
| Dr. Michael A. White Ph.D. | Chief Scientific Officer |
| Dr. Darrin M. Beaupre M.D., Ph.D. | Chief Medical Officer |
| Dr. Joshua Bleharski Ph.D. | Chief Financial Officer |
| Dr. Paul A. Barsanti Ph.D. | Chief Technology Officer |
| Douglas B. Snyder | Senior Vice President and General Counsel |
| Francine Zelaya | Vice President and Head of Human Resources |
| Mick O'Quigley | Chief of Staff and Clinical Development |
| Daniel A. Simon | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 18, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 18, 2025 | 10-K | Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | 8-K | Current Report |
| Feb 10, 2025 | 8-K | Current Report |
| Feb 5, 2025 | SCHEDULE 13G/A | Filing |
| Dec 30, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |